NKTX$2.80
Chart
Performance
Key Stats
AI NKTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldNkarta, Inc. is a clinical-stage biopharmaceutical company with a focus on novel cell therapies. While it operates in a high-potential thematic area (biotechnology/oncology), its current financial state and performance metrics indicate significant risks and a need for further clinical validation. The stock exhibits mixed technical signals.
Thematic
Nkarta operates within the cutting-edge field of cell therapy, targeting oncology and autoimmune diseases. This sector offers substantial growth potential driven by advancements in genetic engineering and a growing understanding of immune system modulation. The company's focus on Natural Killer (NK) cells is a key differentiating factor.
Fundamental
Nkarta is a pre-revenue company with significant operating losses and negative free cash flow. While it possesses substantial cash reserves, its burn rate is high, necessitating future financing rounds. Valuation metrics are not meaningful due to lack of revenue and profitability.
Technical
The stock has experienced significant volatility and a steep decline over the past year. While there are some short-term indicators suggesting potential for a bounce, the overall trend remains bearish, with key moving averages acting as resistance. Trading volume is currently lower than average.
| Factor | Score |
|---|---|
| Biotechnology & Cell Therapy Advancement | 80 |
| Oncology Treatment Innovation | 75 |
| Autoimmune Disease Therapeutics | 70 |
| Biotech Regulatory Landscape | 50 |
| Competition in Cell Therapy | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 40 |
| Cash Flow | 15 |
| Debt Level | 35 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 55 |
| Volume Confirmation | 40 |
| Support & Resistance | 60 |
| MACD | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Innovative Biopharmaceutical Focus
Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing natural killer (NK) cell therapies for cancer and autoimmune diseases. This specialized focus targets significant unmet medical needs.
Promising CAR NK Cell Therapy
The company's lead product candidate, NKX019, a CAR NK therapy targeting CD19, is in Phase 1 clinical trials for multiple autoimmune diseases, including lupus nephritis and systemic lupus erythematosus. Positive trial outcomes could lead to significant market entry.
Bearish Points (8)
Consistent Net Losses and No Revenue
The company has consistently reported significant net losses (e.g., -$108.79 million in 2024Q4, -$117.50 million in 2023Q4) and no revenue, which is typical for a clinical-stage biopharma but highlights the speculative nature of the investment.
Negative Earnings Per Share (EPS)
The EPS TTM is negative (-$1.45), and the Price-to-Earnings (P/E) ratio is not applicable or negative (-1.8 TTM), indicating the company is not currently profitable on a per-share basis.
Calendar
August 2025
12
Next Earnings Date
H: $-0.25
A: $-0.35
L: $-0.50
Profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Seasonals
Price Target
12.80 USD
The 39 analysts offering 1 year price forecasts for NKTX have a max estimate of 18.00 and a min estimate of 8.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in the development of off-the-shelf, induced pluripotent stem cell (iPSC)-derived NK and T cell immunotherapies for cancer.
Weight: 90
A leader in the development of allogeneic (off-the-shelf) CAR-T cell therapies, representing a closely related and competing therapeutic modality in oncology.
Weight: 88
Developing allogeneic cell therapies, including NK cells, derived from placental sources, focusing on oncology and other indications.
Weight: 85
Pioneer in CRISPR-Cas9 gene-editing technology, essential for developing and enhancing next-generation allogeneic cell therapies (including NK cells).